{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.26","upperLimit":"13.17","value":"10.6"},{"groupId":"OG001","lowerLimit":"10.12","upperLimit":"12.42","value":"11.1"}]}],"title":"Weight Loss by 5%"},{"categories":[{"measurements":[{"comment":"The median and upper bound of the confidence interval could not be calculated using the Kaplan-Meier method","groupId":"OG000","lowerLimit":"12.65","upperLimit":"NA","value":"NA"},{"comment":"The upper bound of the confidence interval could not be calculated using the Kaplan-Meier method","groupId":"OG001","lowerLimit":"14.23","upperLimit":"NA","value":"20.3"}]}],"title":"Weight Loss by 10%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"598"},{"groupId":"OG001","value":"602"}],"units":"Participants"}],"description":"Time to definitive weight loss was defined as the time to first occurrence of ≥5% or ≥10% decrease in body weight from baseline. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed on ITT population.","reportingStatus":"POSTED","timeFrame":"From baseline until death or study cut-off date (maximum duration: 48 months)","title":"Time to Definitive Weight Loss by 5% and 10% From Baseline","type":"SECONDARY","unitOfMeasure":"months"}